340 related articles for article (PubMed ID: 29182777)
21. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Park S; Park S; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Kim YW; Heo DS
Korean J Intern Med; 2016 Nov; 31(6):1140-1149. PubMed ID: 27017943
[TBL] [Abstract][Full Text] [Related]
22. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
23. Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer.
Yildirim M; Yildiz M; Duman E; Goktas S; Kaya V
J BUON; 2013; 18(3):728-32. PubMed ID: 24065491
[TBL] [Abstract][Full Text] [Related]
24. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic evaluation of nutritional indicators in patients with limited-stage small cell lung cancer].
Zhang JQ; Wang YY; Xu KP; Qi J; Wang X; Xu LM; Liu NN; Zhao LJ; Wang P
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):937-942. PubMed ID: 31874552
[No Abstract] [Full Text] [Related]
26. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.
Wiersma TG; Dahele M; Verbakel WF; van de Ven PM; de Haan PF; Smit EF; van Reij EJ; Slotman BJ; Senan S
Lung Cancer; 2013 Apr; 80(1):62-7. PubMed ID: 23357464
[TBL] [Abstract][Full Text] [Related]
27. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy.
Liu C; Jing W; An N; Li A; Yan W; Zhu H; Yu J
J Transl Med; 2019 Oct; 17(1):344. PubMed ID: 31623615
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.
Hong J; Liao Z; Zhuang Y; Levy LB; Sheu T; Heymach JV; Nguyen QN; Xu T; Komaki R; Gomez DR
Am J Clin Oncol; 2018 Jan; 41(1):46-52. PubMed ID: 26535988
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
33. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
Lam VK; Bentzen SM; Mohindra P; Nichols EM; Bhooshan N; Vyfhuis M; Scilla KA; Feigenberg SJ; Edelman MJ; Feliciano JL
Lung Cancer; 2017 Feb; 104():52-57. PubMed ID: 28213000
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
35. Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
Takada K; Shimokawa M; Akamine T; Ono Y; Haro A; Osoegawa A; Tagawa T; Mori M
Anticancer Res; 2019 Apr; 39(4):1987-1996. PubMed ID: 30952742
[TBL] [Abstract][Full Text] [Related]
36. [Review of chemoradiotherapy followed by surgical resection in locally advanced non-small-cell lung cancer].
Futamura Y; Sawa T; Hasegawa T; Horiba A; Ishiguro T; Yoshida T; Kinoshita T; Marui T; Murakami E; Azuma K; Murakawa S; Iida T
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2390-2. PubMed ID: 23268087
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer.
Kishi T; Nakamura A; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Kodama Y; Takaori K; Mizowaki T; Hiraoka M
Pancreatology; 2015; 15(6):694-700. PubMed ID: 26601881
[TBL] [Abstract][Full Text] [Related]
38. Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE; Owonikoko TK; Ramalingam SS; Curran WJ; Higgins KA
Clin Lung Cancer; 2017 Nov; 18(6):706-718. PubMed ID: 28601387
[TBL] [Abstract][Full Text] [Related]
39. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.
Ito H; Matsuo Y; Ohtsu S; Nishimura T; Terada Y; Sakamoto T; Mizowaki T
Int J Clin Oncol; 2020 Feb; 25(2):274-281. PubMed ID: 31667664
[TBL] [Abstract][Full Text] [Related]
40. Excessive splenic volume is an unfavorable prognostic factor in patients with non-small cell lung cancer treated with chemoradiotherapy.
Guo J; Wang L; Wang X; Li L; Lü Y; Wang C; Hao C; Zhang J
Medicine (Baltimore); 2020 Dec; 99(49):e23321. PubMed ID: 33285708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
